Stock Analysis
The World Is Becoming Desperate About Deflation
Negative rates reveal global deflation risks, central banks' desperation signals weak growth, rising debt, and fragile economic recovery.
SoftBank’s Big Plan For A Smarter Internet Is Brilliant
Masayoshi Son’s $100B SoftBank Vision Fund is a bold bet on AI, IoT, and a smarter internet that could redefine our future.
Don’t Blame Amazon for The Ice Age in Retail
I was on Fox Business discussing why Amazon should not be blamed for all the troubles in retail-land.
Why Amazon Will Not Kill This Business
Amazon grocery retail faces big hurdles: habits, perishables, and low margins. Tesco shows why this business isn’t so easy to disrupt.
It’s Not Just Amazon’s Fault
It’s not just Amazon. Retail industry challenges stem from phones, health care, fashion shifts, and too many stores chasing shrinking wallets.
The Warren Buffett & Charlie Munger Show
At the Warren Buffett and Charlie Munger Show, tens of thousands gather for lessons in investing, wisdom, and wit from two icons of finance.
Good Companies Don’t Always Make Good Stocks
Dividend investing risks are real, Coca-Cola proves a strong brand isn’t always a strong stock when growth slows and valuations stay high.
Finding High-Quality Companies Today
Markets look stretched, but finding high-quality companies at the right price is still possible with patience and a focus on value.
What Not to Buy in Today’s Stock Market
With overvalued stocks everywhere, chasing yield is dangerous. Caution and patience matter more than fear of missing out in today’s market.
How To Stay Rational In the Irrational World
Subscribe to our 8-email series titled “How to Make Your Investments Succeed in the Long Run.”
Read This Before You Buy Your Next Stock
Stock investing research is essential - don’t buy based on articles alone. Test assumptions, dig deeper, and build conviction before investing.
Why Cognizant Shines Brighter as a Stock Pick
Cognizant stock offers growth, cash strength, and activist-driven upside—making it one of the most compelling picks in outsourcing today.
The Pharma Stocks We’re Buying Now
We’re buying pharma stocks - Mylan and McKesson - for their cash flows, pricing power, and growth, all at valuations too cheap to ignore.
Trump Hates Them – We Love Them
Despite Trump’s attacks, pharmaceutical stocks like Amgen, Allergan, and Gilead remain durable businesses with pricing power and growth tailwinds.
Apple vs Coke
Apple vs Coke highlights why valuation matters - great companies don’t always equal great stocks if prices ignore growth headwinds.
Amgen – Biology vs. Chemistry
Amgen stock shows why biotech beats pharma - slower patent cliffs, strong pipeline, solid balance sheet, and growth tailwinds from aging demographics.
Purchase of Allergan and Sale of Teva
Selling Teva, buying Allergan: Allergan stock offers growth, cash strength, and smart capital allocation after selling its generics business
Trump. Embracing Volatility We Are
Trump brings uncertainty, but uncertainty isn’t risk. With the right horizon and research, market volatility can be an investor’s best ally.
The Dangers of Dividend Obsession
Dividend obsession can be dangerous, focusing only on yield while ignoring growth and valuation risks turning “safe” stocks into bad bets.
The Persistent Problems of Presidential Elections
We take peaceful transfers of power for granted, yet the persistent problems of presidential elections—money, lies, partisanship—remain.
Gilead, Buy HIV, Get Hepatitis C for Free
Gilead is a paradox: a growing HIV business and a shrinking Hepatitis C market. Investors miss the balance, but we couldn’t kill GILD’s case.
